Tilray Guidance Cut Challenges Diversification Thesis

What happened

Jefferies reiterated a Buy rating on Tilray but lowered its price target to $19 after management guided fiscal 2027 adjusted EBITDA to $68–75 million, well below the $84 million consensus, sending shares up 3% to just $4 on relief the guidance wasn't worse. The stock now trades far below the prior master report’s $6 bear-case value and suggests the market is discounting severe profitability headwinds. This EBITDA shortfall, combined with ongoing cash burn and the looming U.S. hemp-THC ban, raises serious doubts about the diversified platform’s ability to generate sustainable returns. While Jefferies sees long-term value, the near-term operational reality points to a company still struggling to convert scale into real earnings. The sharp disconnect between analyst cheer and market pricing emphasizes that Tilray remains a high-risk, policy-dependent story rather than a resilient consumer staple.

Implication

The FY27 EBITDA shortfall confirms that profitability remains distant despite diversification efforts, undermining the bull case that operational improvements would offset regulatory risks. At $4, the stock prices in both the potential loss of hemp-THC revenue and continued cash burn, making the $19 Jefferies target seem disconnected from fundamentals. Without clear catalysts—such as sustained positive free cash flow or concrete U.S. policy softening—the risk/reward is unattractive. Investors should await evidence that the international cannabis growth and cost cuts are translating into durable earnings before committing capital. The WAIT rating from the master report now looks even more appropriate given the heightened uncertainty.

Thesis delta

Management’s FY27 EBITDA guidance of $68–75 million is well below prior estimates, signaling that profitability improvements are lagging expectations. This weakens the prior thesis that gradual operational gains would buffer regulatory headwinds, shifting the narrative toward a prolonged loss-making phase with fewer near-term catalysts.